Plexus Earnings Call Transcripts
Fiscal Year 2026
-
Record Q3 revenue and margin exceeded guidance, driven by strong demand and new program wins across all sectors. Fiscal 2026 revenue growth is expected to surpass 20%, with continued margin expansion and robust free cash flow in 2027.
-
Q2 2026 saw 19% year-over-year revenue growth and record new program wins, with strong performance across all sectors. Fiscal 2026 guidance was raised to mid-teens revenue growth and robust margins, supported by operational efficiency and proactive supply chain management.
-
The company is experiencing strong growth momentum, driven by ramping programs in healthcare, industrial, and aerospace/defense sectors. Investments in automation, AI, and global capacity expansion are improving margins and operational efficiency, while proactive supply chain management and a robust balance sheet support continued growth and shareholder returns.
-
The meeting covered board elections, executive compensation, and auditor ratification, all of which passed by majority vote. Fiscal 2025 featured strong financial results, sustainability achievements, and ongoing strategic investments. No shareholder questions were raised.
-
Revenue grew 10% year-over-year to $1.07B, with strong program ramps and record wins in aerospace and defense. Guidance for Q2 and FY26 was raised, with robust demand, margin expansion, and $100M free cash flow expected. Automation and AI investments are driving efficiency gains.
Fiscal Year 2025
-
Fiscal 2025 saw strong revenue growth, margin expansion, and robust free cash flow, driven by new program wins and operational efficiency. Fiscal 2026 is expected to deliver above-market revenue growth, continued margin strength, and significant investments in automation and capacity.
-
Q3 FY25 delivered sequential revenue growth, 6% non-GAAP operating margin, and strong free cash flow, with robust new program wins and accelerated share repurchases. FY26 outlook anticipates healthy growth across all sectors and sustained profitability.
-
Q2 2025 results met or exceeded guidance, with $980M revenue, 5.7% operating margin, and $1.66 EPS. Strong program wins, robust free cash flow, and broad-based growth in healthcare, aerospace/defense, and semi-cap sectors support a positive outlook for sequential revenue and EPS growth in 2025.
-
The company is focused on complex product markets in healthcare, industrial, and aerospace/defense, achieving strong margins and record free cash flow. Growth is supported by engineering services, global capacity, and operational efficiency, with a flexible approach to tariffs and supply chain shifts.
-
Q1 FY2025 delivered strong results with revenue of $976M and non-GAAP EPS of $1.73, exceeding guidance. Growth is expected across all sectors in FY2025, with semi-cap outpacing the market and robust free cash flow forecasted up to $100M. Commercial aerospace remains a near-term headwind.
Fiscal Year 2024
-
Exceptional Q4 and FY24 results with record free cash flow, margin expansion, and strong program wins. FY25 guidance anticipates robust aerospace and defense growth, moderate gains in healthcare and industrial, and continued operational efficiency.
-
Fiscal Q3 saw strong revenue, margin, and free cash flow, with record program wins and positive customer sentiment. Guidance points to sequential growth and robust margins into Q4 and FY25, supported by sector momentum and operational efficiencies.
-
The company is focused on complex, regulated markets and has outpaced industry growth, with strong recent performance in aerospace and healthcare. Operational improvements, AI-driven supply chain management, and a focus on free cash flow are driving financial strength, while a balanced portfolio and global footprint support future growth.